Researchers propose the 'Aging Purinome' framework to map purinergic signaling changes in inflammaging
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
A newly proposed systems-level framework, the Aging Purinome, models how age-associated remodeling of extracellular purinergic signaling and NAD+ metabolism drives sterile inflammation, providing a structured basis for drug discovery.
What happened
In a paper published in Ageing Research Reviews, researchers proposed the 'Aging Purinome' as a systems-level framework detailing the age-associated remodeling of extracellular purinergic signaling.
The framework integrates extracellular nucleotides/nucleosides, nucleotide release/transport, ectonucleotidases, P2X, P2Y, and adenosine receptors, as well as interconnected metabolic pathways.
The authors identified age-related alterations in extracellular ATP availability, changes in receptor repertoires, dysregulation of the CD39-CD73-adenosine axis, and increased CD38-dependent NAD+ consumption as key contributors to chronic sterile inflammation (inflammaging).
Why it matters
Inflammaging is a key driver of neurodegenerative, cardiometabolic, and neoplastic disorders, but the molecular networks connecting it to other aging hallmarks have remained incomplete.
The Aging Purinome links P2X7-NLRP3 signaling and other purinergic pathways directly to cellular senescence, mitochondrial dysfunction, and impaired inflammatory resolution, providing drug developers with distinct, testable molecular targets.
Market impact
The research highlights pharmacological modulation of purinergic and NAD+-related pathways, such as the CD39-CD73-adenosine axis, as potential strategies to restore homeostatic signaling.
The proposed role of CD38-dependent NAD+ consumption in purinergic remodeling supports therapeutic strategies targeting NAD+ degradation to prevent chronic inflammation.
What comes next
Future mechanistic and translational studies to validate pharmacological interventions targeting P2X7, CD38, or specific P2X and P2Y receptor pathways in preclinical models of age-related diseases.
Company relevance
Structured relationships recorded at publication time. Sector exposure is thematic only — it does not mean the company took part. Not market data.
- Mitrix Bio
Sector exposure · MECHANISM
The proposed Aging Purinome framework asserts that purinergic remodeling influences age-related mitochondrial dysfunction, a metabolic area of interest relevant to Mitrix Bio's historical and preclinical focus. (LONGEFI analysis)
- Unity Biotechnology
Sector exposure · MECHANISM
The framework links age-dependent purinergic communication to cellular senescence, which relates to Unity Biotechnology's historical and preclinical program focus on senolytics. (LONGEFI analysis)
Sources
- NCBIPUBMED:LONGEVITY_RESEARCH